ONC vs. TEM: BeOne Medicines vs. Tempus AI Stock Comparison

Company Profile

BeOne Medicines (ONC) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

BeOne Medicines (ONC) has been public since February 3, 2016, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Tempus AI (TEM) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while BeOne Medicines (ONC) is defensive at 0.59 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile BeOne Medicines (ONC) reports 13.86%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BeOne Medicines (ONC) reports 22.15%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while BeOne Medicines (ONC) at 40.23% is closer to the peer norm — faster top-line expansion for TEM.

Neither BeOne Medicines (ONC) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both BeOne Medicines (ONC) at 3.55 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BeOne Medicines (ONC) at 0.35 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither BeOne Medicines (ONC) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BeOne Medicines (ONC) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

Valuation Metrics